学会発表（国内学会）

2026年度

2026.05 第11回 日本がんサポーティブケア学会

• がん患者におけるソーシャル・ネットワーキング・サービスの利用実態に関するアンケート調査
  森川日都美、武田弘幸、小倉孝氏、久保田洋平、永田祐介、堀江良樹、梅本久美子、新井裕之、伊澤直樹、小川光波美、藤本晴美、砂川優.

• 免疫関連有害事象・副腎不全に対する長期ステロイド投与下のACTH/コルチゾール定期測定の有用性
  小野田彩花, 伊澤 直樹, 八木 智也, 河合 広樹, 牧野 有花, 小川 和起, 久保田 洋平, 永田 祐介, 堀江 良樹, 武田 弘幸, 梅本久美子, 新井 裕之, 砂川 優.

2026.06 第34回日本乳癌学会学術総会

• 乳がん診療専門クリニックにおけるePRO利用と臨床経過アウトカムに関する後方視的調査
  神蔵奈々, 堀江良樹, ⽥邊幸⼦, 川本久紀, 久保⽥洋平, 武⽥弘幸, 永⽥祐介, 梅本久美⼦, 新井裕之, 伊澤直樹, 砂川優, 福⽥護.

2026.06 第80回日本食道学会学術集会

• Stage IVB食道癌に対する免疫チェックポイント阻害薬併用療法の食道穿孔発生率の検討
  八木智也, 久保田洋平, 永田 祐介, 河合広樹, 牧野有花, 小川和起, 武田弘幸, 伊澤直樹, 砂川優.

2026.07 第105回大腸癌研究会学術集会

• MSI-H/dMMR切除不能大腸癌に対するトリフルリジン・チピラシル±ベバシズマブ療法の多施設共同後方視的研究
  長谷川 裕子, 伊澤 直樹, 三谷 誠一郎, 川上 武志, 結城 敏志, 平野 秀和, 三島 沙織, 舛石 俊樹.

2025年度

2025.06 第79回日本食道学会学術集会

• 通過障害合併StageIVB食道癌に対するICI併用化学療法の実用的第2相試験
  永田祐介、稲垣千晶、菅谷明徳、平田賢郎、對馬隆浩、舛石俊樹、森脇俊和、長谷善明、原田和治、田栗正隆、砂川　優.

2025.09 日本内科学会　第707回関東地方会

• 化学療法が奏功した縦郭進展を伴う胸椎原発悪性骨巨細胞腫の1例
  牧野有花, 武田弘幸, 小川和起, 杉浦義弥, 大池信之, 久保田洋平, 伊澤直樹, 砂川優.

2025.10 第63回日本癌治療学会学術集会

• A retrospective observational study to evaluate the efficacy of trifluridine/tipiracil ± bevacizumab in metastatic colorectal cancer with MSI-high/deficient MMR
  Keiji Sugiyama, Hiroko Hasegawa, Naoki Takahashi, Naoki Izawa, Seiichiro Mitani, Takeshi Kawakami, Satoshi Yuki, Hidekazu Hirano, Saori Mishima, Tetsuro Hamano, Toshiki Masuishi.
• MSI-H/dMMR進行大腸癌に対するFTD/TPI±BEVに関する後方視的多施設共同研究
  杉山 圭司, 長谷川 裕子, 稲本 林, 伊澤 直樹, 三谷 誠一郎, 川上 武志, 結城 敏志, 平野 秀和, 三島 沙織, 濱野 鉄太郎, 舛石 俊樹.
• 乳癌患者における化学療法誘発性脱毛に対する新しい頭皮冷却装置の使用経験
  敦賀 智, 川本 久紀, 本吉 愛, 白 英, 志茂 彩華, 都築 麻紀子, 黒田 貴子, 松尾 益佳, 瀧下 茉莉子, 堀江 良樹, 福田 護, 津川 浩一郎.
• 婦人科癌薬物療法中患者に対するelectric patient reported outcome（ePRO）の臨床導入
  宮澤 千夏, 久慈 志保, 石井 雅人, 竹内 淳, 大原 樹, 堀江 良樹, 鈴木 直.

2025.11 第80回日本大腸肛門病学会学術集会

• Long-term Outcomes of a Multicenter Prospective Phase II Trial of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: The ENSEMBLE-2 Study
  Tatsuya Kinjo, Yoshinori Kagawa, Jun Watanabe, Koji Ando, Mamoru Uemura, Koichi Okutani, Yujiro Nishizawa, Yusuke Suwa, Yoshiaki Fujimoto, Nobuhiro Matsuhashi, Naoki Izawa, Osamu Muto, Masaaki Mishiro, Hideaki Bando, Koji Oba, Takayuki Yoshino, Eiji Oki.

2026.3 第712回内科関東地方会

• 免疫チェックポイント阻害薬併用療法により長期病勢制御が得られたAFP産生胃癌の1例
  河合広樹, 武田弘幸,八木智也,牧野有花,小川和起,砂川優.

2026.3 第23回日本臨床腫瘍学会学術集会（JSMO2026）

• Clinical Utility of Liquid CGP in Colorectal Cancer: Real-World Single-Institution Experience.
  Hiroyuki Takeda, Kiyomi Imoto, Tomoya Yagi, Hiroki Kawai, Yuka Makino, Kazuki Ogawa, Yusuke Nagata, Yohei Kubota, Yoshiki Horie, Kumiko Umemoto, Hiroyuki Arai, Takashi Ogura, Naoki Izawa, Yu Sunakawa.
• Early Safety Outcomes of Biweekly Versus Conventional FTD/TPI Plus Bevacizumab in Colorectal Cancer: PRABITAS Analysis.
  Tomoki Sakakida, Masako Asayama, Yusuke Suwa, Takaya Shimura, Seiichiro Mitani,Akitaka Makiyama, Hiroyuki Takeda, Hiroshi Matsuoka, Mitsuru Yokota, Takano Yoshinao, Masashi Hattori, Hisanobu Oda, Takeshi Kajiwara, Kohei Ogawa, Nobuhiro Shibata, Kentaro Sawada, Takato Yomoda, Toshihiro Kudo, Kenta Murotani, Hiroya Taniguchi.
• SMARCB1欠失を伴う原発不明未分化癌に対しFOLFOX+ニボルマブ併用療法が奏効した1例.
  山﨑 彩加, 齋藤 陽介, 武田 弘幸, 鈴木 修平, 山田 雄太, 髙橋 鴻志, 熊西 亮介, 福井 忠久, 高橋 雅信.
• 集学的治療により長期無再発生存を得られた縦隔原発混合性胚細胞腫瘍の1例.
  小川 和起, 武田 弘幸, 河合 広樹, 八木 智也, 牧野 有花, 久保田 洋平, 永田 祐介, 堀江 良樹, 新井 裕之, 梅本 久美子, 伊澤 直樹, 砂川 優.
• 胆膵系悪性腫瘍における組織CGP不適格例に対する対応とリキッドCGPの有用性.
  井本 清美, 砂川 優, 新井 裕之, 武田 弘幸, 山本 博幸, 永田 祐介, 久保田 洋平, 堀江 良樹, 梅本 久美子, 小倉 孝氏, 伊澤 直樹, 佐藤 知雄, 野原 祥夫, 山野 喜久.
• 外来化学療法における事前採血が待機時間に与える影響に関する前向き観察研究.
  砂川 優, 新井 裕之, 久保田 洋平, 永田 祐介, 武田 弘幸, 梅本 久美子, 堀江 良樹, 伊澤 直樹, 小倉 孝氏, 岡塚 貴世志, 岡村 裕太, 細山田 俊英, 伊豆丸 裕美, 榊原 由紀子, 添田 純平, 高久 玲音.
• ゲノムプロファイリングに基づいたダブラフェニブ+トラメチニブ療法が奏効した膵腺房細胞癌の一例.
  牧野 有花 , 永田 祐介, 八木 智也, 河合 広樹, 小川 和起, 久保田 洋平, 堀江 良樹, 武田 弘幸, 梅本 久美子, 新井 裕之, 小倉 孝氏, 伊澤 直樹, 砂川 優.
• がん領域における遠隔医療を活用した臨床試験リモート・プレスクリーニングの実現可能性と臨床的有用性.
  砂川 優 , 増原 直子, 梅本 久美子, 新井 裕之, 永田 祐介, 久保田 洋平, 武田 弘幸, 堀江 良樹, 小倉 孝氏, 伊澤 直樹.
• 切除不能大腸癌に対するFTD/TPI+BEVの従来法と隔週法の実用的ランダム化第Ⅲ相試験における治療早期副作用の比較：PRABITAS試験初回報告.
  [演者] 榊田 智喜, [共同演者] 朝山 雅子, 諏訪 雄亮, 志村 貴也, 三谷 誠一郎, 牧山 明資, 武田 弘幸, 松岡 宏, 横田 満, 髙野 祥直, 服部 正嗣, 小田 尚伸, 梶原 猛史, 小川 浩平, 柴田 伸弘, 澤田 憲太郎, 四方田 隆任, 工藤 敏啓, 室谷 健太, 谷口 浩也.
• がん領域における遠隔医療を活用した臨床試験リモート・プレスクリーニングの実現可能性と臨床的有用性.
  [演者] 砂川 優, [共同演者] 増原 直子, 梅本 久美子, 新井 裕之, 永田 祐介, 久保田 洋平, 武田 弘幸, 堀江 良樹, 小倉 孝氏, 伊澤 直樹.
• EGFR遺伝子増幅陽性切除不能固形がんに対するネシツムマブの第II相バスケット試験.
  [演者] 舛石 俊樹, [共同演者]三谷 誠一郎, 野村 基雄, 平田 賢郎, 坂東 英明, 砂川 優:, 中西 香企, 高橋 直樹, 三浦 裕司, 濱内 諭, 江崎 泰斗, 岡本 渉, 工藤 千穂, 中村 能章, 林 秀敏, 安藤 昌彦, 鶴田 敏久, 鍬塚 八千代, 室 圭, 小寺 泰弘.
• 高度通過障害を合併したStage IVB食道癌患者に対する治療選択の実態調査.
  [演者] 永田 祐介, [共同演者] 山口 敏史, 髙橋 秀和, 東 重慶, 天沼 裕介, 吉井 貴子, 中村 将人, 岡本 浩一, 田中 善宏, 中田 晃暢, 佐竹 悠良, 竹野 淳, 木村 和恵, 山口 太輔, 高山 治, 砂川 優.
• cfDNAで同定されたHER2増幅固形がんに対するトラスツズマブ デルクステカンの臨床的有用性―HERALDおよびGOZILA試験を用いた実臨床治療との比較―.
  [演者] 水野 太朗, [共同演者] 谷口 浩也, 佐藤 太郎, 坂東 英明, 門脇 重憲, 仁科 科裕, 砂川 優, 小松 嘉人, 江崎 泰斗, 加藤 健, 結城 敏志, 加藤 健志, 山口 研成, 上野 誠, 堀田 洋介, 佐藤 暁洋, 八木澤 允貴, 吉野 孝之, 中村 能章.
• CodeBreaK300/101試験より大腸癌に対するソトラシブ+パニツムマブ併用療法のアジアおよび他地域のサブグループ解析.
  [演者] 江崎 泰斗, [共同演者] 久保木 恭利, Jin-Beom Ahn, 砂川 優, 山口 研成, 津田 政広, 山﨑 健太郎, 仁科 智裕, 佐藤 太郎, 原 浩樹, Kun-Huei Yeh, Jane Hippenmeyer, Joseph Chao, Chidozie Nduka, Qui Tran, 舛石 俊樹, Tae Won Kim.
• 大腸癌患者におけるカペシタビンの薬物動態に及ぼす人参養栄湯の影響.
  [演者] 相楽 勇人, [共同演者] 篠崎 勝則, 吉田 直久, 高木 剛, 伊藤 慎吾, 宗本 義則, 藤田 秀人, 進藤 吉明, 土橋 賢司, 馬場 英司, 根来 裕二, 新井 裕之, 白石 猛, 西内 崇将, 森田 智視, 辻 晃仁, 元雄 良治, 三浦 昌朋.
• 切除不能膵癌における予測バイオマーカーとしての個別化ctDNA動態の臨床的有用性：ARTEMIS-PC研究.
  [演者] 澁木 太郎, [共同演者] 坂東 英明, 上野 誠, 池澤 賢治, 奥坂 拓志, 杉浦 禎一, 亀井 敬子, 小松 嘉人, 海野 倫明, 由上 博喜, 岩下 拓司, 梅本 久美子, Emily Westheimer, Keir Violaceae, Jacquelyn Reuther, Jianhua Zhao, Robert Daber, 吉野 孝之, 池田 公史.

2026.3 第98回日本胃癌学会総会

• 切除不能胃脂肪肉腫に対し化学療法後に根治切除が可能となった1例
  [演者] 黒瀬明日香、 [共同演者]　久保田洋平、河合宏樹、八木智也、牧野有花、小川和起、永田祐介、堀江良樹、武田 弘幸、新井 裕之、梅本久美子、伊澤直樹、柴田真知、増田 哲之、樋渡 正樹、塚本 芳嗣、久恒 靖人、松森智子、榎本武治、民上 真也、砂川優. .

2024年度

2024.07 第78回日本食道学会学術集会

• 通過障害を合併したStage IVB食道癌に対する治療選択と臨床転帰の評価
  永田 祐介、新井 裕之、武田 弘幸、久保田 洋平、梅本 久美子、伊澤 直樹、中村 直樹、砂川 優.

2024.07 第101回大腸癌研究会学術集会

• 切除不能進行再発大腸癌（mCRC）における血漿を用いた包括的ゲノムプロファイリング（CGP）のRAS/BRAF変異別の意義
  小川 和起、新井 裕之、武田 弘幸、久保田 洋平、永田 祐介、内田 吉保、牧野 有花、堀江 良樹、梅本 久美子、伊澤 直樹、中村 能章、吉野 孝之、砂川 優.

2024.07 第79回日本消化器外科学会

• 局所進行下部直腸癌における術前治療の治療成績と展望
  賀川義規, 渡邉純, 伊澤直樹, 沖英次.

2024.09 第83回日本癌学会学術総会

• 胃癌患者におけるニボルマブの新規予後予測バイオマーカーとしての血中OXPHOS 関連遺伝子シグネチャーとSNPs
  稲垣 千晶, 的場 亮, 飯島 寛, 藪崎 裕, 松山 仁, 高橋 正純, 木藤 陽介, 赤丸 祐介, 石黒 敦, 川端 良平, 坂本 康寛, 井上 永介, 市川 度, 藤井 雅志, 砂川 優.

2024.10 第62回日本癌治療学会学術集会

• Genomic profile differences between primary and recurrent tumors in recurrent gastric cancer: the Liquid-GEAR Study.
  Shinichi Nishina, Hiroyuki Takeda, Ryohei Kawabata, Atsushi Ishiguro, Masazumi Takahashi, Shuhei Suzuki, Takahisa Suzuki, Jin Matsuyama, Yasufumi Otsuki, Yusuke Akamaru, Naoki Takegawa, Takashi Nomura, Yosuke Kito, Masaki Takahashi, Yu Sunakawa.
• Final results of the JACCRO CC-16：ramucirumab plus FOLFIRI for RAS wild-type anti-EGFR antibody refractory metastatic colorectal cancer.
  赤澤 直也, 池永 雅一, 秋山 泰樹, 松浦 正徒, 中村 将人, 佐川 保, 塩澤 学, 太田 博文, 小髙 雅人, 大北 仁裕, 砂川 優, 竹内 正弘, 市川 度, 藤井 雅志, 辻 晃仁.
• An Observational Study of BRAF Inhibitor Combination Therapy for BRAF-mutated Metastatic Colorectal Cancer Patients：Real-World Evidence from BEETS Trial（JACCRO CC-18）.
  稲垣 千晶, 傳田 忠道, 小谷 大輔, 井上 永介, 柏田 知美, 三原 良明, 天貝 賢二, 諏訪 雄亮, 太田 高志, 結城 敏志, 塩澤 学, 辻 晃仁, 室 圭, 市川 度, 砂川 優.
• Guradant360 CDxがん遺伝子パネル検査の初期成績―20例の経験から―.
  市川 眞琴, 髙橋 威洋, 関川 高志, 井本 清美, 砂川 優, 市川 度.
• 再発胃癌における原発腫瘍と再発腫瘍のゲノムプロファイルの違い：Liquid-GEAR.
  仁科 慎一, 武田 弘幸, 川端 良平, 石黒 敦, 高橋 正純, 鈴木 修平, 鈴木 崇久, 松山 仁, 大槻 泰史, 赤丸 祐介, 武川 直樹, 野村 尚, 木藤 陽介, 高橋 政樹, 砂川 優.
• ARCAD Asiaデータベースを活用した解析の実例.
  山崎 健太郎, 沖 英次, 坂東 英明, 設楽 紘平, 寺島 雅典, 掛地 吉弘, 安藤 幸慈, 賀川 義規, 砂川 優, 佐竹 悠良, 結城 敏志, 大庭 幸治, 吉野 孝之, 大津 敦, 前原 喜彦.
• Combined Analysis of ENSEMBLE-1 and ENSEMBLE-2 Phase II studies Evaluating TNT in Local Advanced Rectal Cancer in Japan.
  \\\[演者] 賀川 義規, \\\[共同演者] 渡邉 純, 安藤 幸滋, 植村 守, 伊澤 直樹, 松橋 延壽, 武藤 理, 江見 泰徳, 金城 達也, 諏訪 雄亮, 西沢 佑次郎, 竹政 伊知朗, 大庭 幸治, 沖 英次.

2024.11 第86回日本臨床外科学会学術集会

• 日本における局所進行直腸癌に対するTNTを評価した第II相試験ENSEMBLE-1とENSEMBLE-2の統合解析
  三代雅明, 伊澤直樹, 賀川義規, 渡邉純.

2025.02 日本臨床試験学会第16回学術集会総会

• がん領域における遠隔医療・遠隔治験に対する患者・医療従事者の声～アンケート調査結果より～
  川上 武志, 佐藤 拓弥, 松永 拓真, 田村 祐子, 佐竹 悠良, 砂川 優, 谷口 浩也.

2025.03 第22回日本臨床腫瘍学会学術集会

• 再発胃癌・胃食道接合部癌におけるActionableな遺伝子異常の変化と臨床的特徴
  武田 弘幸, 川端 良平, 石黒 敦, 仁科 慎一, 高橋 正純, 鈴木 修平, 鈴木 崇久, 松山 仁, 大槻 泰史, 赤丸 祐介, 武川 直樹, 野村 尚, 木藤 陽介, 藪崎 裕, 根来 裕二, 牧山 明資, 中村 将人, 高橋 政樹, 砂川 優.

• 血液透析中の消化器癌患者に対するFOLFOX療法の安全性と有効性に関する多施設共同臨床試験
  安井 久晃, 武藤 学, 堀松 高博, 船越 太郎, 片岡 滋貴, 中村 路夫, 山田 武史, 陶山 浩一, 武田 弘幸, 多久 佳成, 後藤 知之, 青山 育雄, 桐島 寿彦, 八隅 秀二郎, 津村 剛彦, 尾崎 由直, 馬場 英司, 勝屋 弘雄, 細川 歩, 魚住 龍史.

• A phase 2 study of mFOLFOX6 plus nivolumab for untreated advanced esophageal squamous-cell cancer: FLONTALE trial
  Yohei Kubota, Shunsuke Ueyama, Takeshi Yamada, Yusuke Amanuma, Mitsuhiro Furuta, Sho Sato, Takahiro Tsushima, Ayako Hata, Kenichiro Tanabe, Yutaro Kubota, Shigenori Kadowaki, Yu Sunakawa.

• 膵癌の細胞診検体を用いたデジタルPCRによるKRAS変異同定の臨床的妥当性の検討
  梅本 久美子, 中原 一有, 大池 信之, 薩田 祐輔, 関根 章裕, 五十嵐 洋介, 永田 裕介, 久保田 洋平, 武田 弘幸, 堀江 良樹, 新井 裕之, 伊澤 直樹, 開 隼人, 野呂瀬 朋子, 小池 淳樹, 立石 敬介, 砂川 優.

• 進行性大腸癌に対するRAS/BRAF変異別のCGP検査の臨床的意義
  小川 和起, 新井 裕之, 牧野 有花, 久保田 洋平, 武田 弘幸, 永田 祐介, 堀江 良樹, 梅本 久美子, 伊澤 直樹, 中村 能章, 吉野 孝之, 砂川 優.

• 血液透析中の消化器癌患者に対するFOLFOX療法の安全性と有効性に関する多施設共同臨床試験
  安井 久晃, 武藤 学, 堀松 高博, 船越 太郎, 片岡 滋貴, 中村 路夫, 山田 武史, 陶山 浩一, 武田 弘幸, 多久 佳成, 後藤 知之, 青山 育雄, 桐島 寿彦, 八隅 秀二郎, 津村 剛彦, 尾崎 由直, 馬場 英司, 勝屋 弘雄, 細川 歩, 魚住 龍史.

• 通過障害合併Stage IVB食道癌における免疫チェックポイント阻害薬併用化学療法の実用的第2相試験
  永田 祐介, 新井 裕之, 伊澤 直樹, 稲垣 千晶, 菅谷 明徳, 平田 賢郎, 對馬 隆浩, 森脇 俊和, 川上 尚人, 原田 和治, 田栗 正隆, 砂川 優.

• 直腸癌に対するtotal neoadjuvant tehrapyの効果を予測するためのctDNA検査 -ENSEMBLE-2試験の結果から-
  永田 祐介, 安藤 幸滋, 賀川 義規, 渡邉 純, 植村 守, 藤本 禎明, 諏訪 雄亮, 西沢 佑次郎, 松橋 信壽, 伊澤 直樹, 武藤 理, 金城 達也, 三代 雅明, 中村 能章, 坂東 英明, 竹政 伊知朗, 大庭 幸治, 吉野 孝之, 沖 英次.

• PROCEED試験(CyberOncology®)でのCyberOncology®の利便性に関するアンケート調査
  古田 光寛, 岡本 渉, 松本 俊彦, 稲垣 千晶, 松原 裕樹, 日野 佳織, 平田 賢郎, 門脇 重憲, 新井 裕之, 細川 歩, 杉本 直俊, 安井 久晃, 野津 昭文, 室 圭.

• RAS野生型大腸癌におけるmodified-FOLFOXIRI+セツキシマブ療法の効果予測臨床因子: DEEPER試験 (JACCRO CC-13)
  砂川 優, 塩澤 学, 東風 貢, 山口 敏史, 三宅 亨, 佐川 保, 岡村 修, 田中 千弘, 松橋 延壽, 若村 邦彦, 吉田 泰一, 村田 幸平, 小髙 雅人, 久保田 祐太郎, 関川 高志, 中村 将人, 竹内 正弘, 市川 度, 藤井 雅志, 辻 晃仁.

• HER2遺伝子変異を有する固形癌に対するMobocertinib+T-DM1併用療法の安全性と有効性を検討する多施設共同第Ia/Ib相バスケット試験(WJOG16022M:HER2 Sand)
  松本 光史, 金村 宙昌, 谷﨑 潤子, 舛石 俊樹, 磯部 大地, 児玉 裕章, 清水 俊雄, 砂川 優, 千葉 康敬, 山本 信之, 中川 和彦, 林 秀敏.

• Random Surivival ForestによるStage III治癒切除胃癌患者の予後予測-START-2試験データを用いた後方視的研究-
  佐藤 弘樹, 市川 度, 吉田 和弘, 小寺 泰弘, 掛地 吉弘, 東風 貢, 尾嶋 仁, 藤谷 和正, 檜原 淳, 武者 信行, 石黒 敦, 北沢 将人, 佐野 力, 豊川 貴弘, 木南 伸一, 瀧 雄介, 竹内 正弘, 砂川 優, 藤井 雅志, 佐野 武.

• 血中遊離DNAによりHER2遺伝子増幅が認められた固形がんに対するトラスツズマブ デルクステカンの多施設共同臨床第II相試験(HERALD/EPOC1806試験) データ アップデート
  西田 尚弘, 佐藤 太郎, 門脇 重憲, 砂川 優, 仁科 智裕, 小松 嘉人, 江崎 泰斗, 小野 宏美, 淺野 雅俊, 平野 奈美, 藤井 誠志, 野村 尚吾, 吉野 孝之, 中村 能章, 佐藤 暁洋, 八木澤 允貴, 谷口 浩也.

• リスク因子を有するBRAF変異型大腸癌に対するエンコラフェニブ、ビニメチニブ、セツキシマブ併用療法:BEETS試験 (JACCRO CC-18)
  古賀 邦林, 井上 永介, 田中 千弘, 工藤 敏啓, 母里 淑子, 木藤 陽介, 勝屋 弘雄, 中村 有貴, 武藤 理, 赤澤 直也, 粂川 陽祐, 中村 路夫, 重安 邦俊, 中村 将人, 佐川 保, 渡邊 龍之, 遠藤 俊吾, 市川 度, 藤井 雅志, 砂川 優.

• MONSTAR-SCREEN-2における組織および血液に基づく遺伝子解析を用いた神経内分泌腫瘍の分子学的特徴
  牛山 心平, 松原 裕樹, 橋本 直佳, 三島 沙織, 門脇 重憲, 岡野 尚弘, 大坪 公士郎, 上野 誠, 大塚 倫之, 砂川 優, 傳田 忠道, 牧山 明資, 江崎 泰斗, 賀川 義規, 高橋 直樹, 朴 将源, 藤澤 孝夫, 中村 能章, 坂東 英明, 吉野 孝之.

• The clinical validity of droplet digital PCR to identify KRAS mutations using blood or cytology specimens in pancreatic cancer.
  Kumiko Umemoto, Kazunari Nakahara, Nobuyuki Ohike, Yusuke Satta, Akihiro Sekine, Yosuke Igarashi, Yusuke Nagata, Yohei Kubota, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Naoki Izawa, Hayato Hiraki, Tomoko Norose, Junki Koike, Ryo Matoba, Satoshi Nishizuka, Keisuke Tateishi, Yu Sunakawa.

学会発表（国際学会）

2026年度

2026.05 ASCO

• BAYONET trial: A Multicenter Phase II trial of Staged Combination with Encorafenib + Binimetinib + Cetuximab following Encorafenib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer.
  Takeshi Yamada, Yuki Matsubara, Hideaki Bando, Mitsuhiro Furuta, Eiji Shinozaki, Naoki Izawa, Kazuaki Harada, Yuta Okumura, Akitaka Makiyama, Hisateru Yasui, Hiroki Osumi, Takeshi Kawakami, Daisuke Kotani, Yoshinori Kagawa, Shogen Boku, Toshihiko Matsumoto, Takeshi Ikeno, Masashi Wakabayashi, Yoshiaki Nakamura, and Takayuki Yoshino.

• Overall survival benefit of doublet versus triplet BRAF inhibitor–based therapy: Insights from the BEETS study (JACCRO CC-18).
  Yuki Matsubara, Taigo Kato, Tomohiro Nishina, Koji Ando, Shugo Yajima, Qingjiang Hu, Hiroshi Tanabe, Shin Kobayashi, Masashi Wakabayashi, Takayuki Yoshino, Eiji Oki, Hideaki Bando, Satoshi Yuki, Michiaki Unno, Naoki Takahashi, Yu Sunakawa, Makoto Ueno, Takeshi Kawakami, Takahiro Kojima, Akitaka Makiyama, Taigo Kato, Tomohiro Nishina, Koji Ando, Shugo Yajima, Qingjiang Hu, Hiroshi Tanabe, Shin Kobayashi, Masashi Wakabayashi, Takayuki Yoshino, Eiji Oki.

• Organ preservation strategy using dostarlimab for dMMR/MSI-H resectable solid tumors with whole-genome–based MRD monitoring (D-CURE: EPOC2401).
  Yuki Matsubara, Taigo Kato, Tomohiro Nishina, Koji Ando, Shugo Yajima, Qingjiang Hu, Hiroshi Tanabe, Shin Kobayashi, Masashi Wakabayashi, Takayuki Yoshino, Eiji Oki, Hideaki Bando, Satoshi Yuki, Michiaki Unno, Naoki Takahashi, Yu Sunakawa, Makoto Ueno, Takeshi Kawakami, Takahiro Kojima, Akitaka Makiyama, Taigo Kato, Tomohiro Nishina, Koji Ando, Shugo Yajima, Qingjiang Hu, Hiroshi Tanabe, Shin Kobayashi, Masashi Wakabayashi, Takayuki Yoshino, Eiji Oki.

• Individualized estimation of benefit from adjuvant docetaxel plus S-1 in stage III gastric cancer using deep learning–based counterfactual survival analysis of the START-2 trial.
  Hiroki Sato, Wataru Ichikawa, Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Yoshihiro Kakeji, Masahiro Takeuchi, Yu Sunakawa, Masashi Fujii, Takeshi Sano.

• A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer.
  Hiroto Matsui, Takeshi Terashima, Takashi Mizuno, Yoshiharu Masaki, Makoto Ueno, Kunihiro Tsuji, Ryosuke Kumanishi, Yoshiki Hirooka, Rei Suzuki, Rie Sugimoto, Kumiko Umemoto, Atsushi Sato, Takayuki Ando, Michiaki Unno, Toshihiko Masui, Hidetoshi Eguchi, Kenichi Yoshimura, Etsuro Hatano, Hiroaki Nagano, Tatsuya Ioka.

• Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M).
  Tomoki Sakakida, Toshiki Masuishi, Takuma Onoe, Keigo Komine, Kan Yonemori, Takao Fujisawa, Kentaro Tokumo, Kazuaki Harada, Satoshi Hamauchi, Taito Esaki, Yukihiko Hiroshima, Satomi Watanabe, Hiroyuki Takeda, Masako Asayama, Waki Hosoda, Hiroya Taniguchi, Hidetoshi Hayashi, Kei Muro.

2026.07 ESMO-GI

• Longitudinal Analysis of ERBB2 Amplification and Genomic Alterations Using Circulating Tumor DNA in Recurrent Gastric or Gastroesophageal Junction Cancer.
  Hiroyuki Takeda, Hiroyuki Arai, Yohei Kubota, Yusuke Nagata, Kumiko Umemoto, Yoshiki Horie, Kazuki Ogawa, Yuka Makino, Hiroki Kawai, Tomoya Yagi, Takashi Ogura, Naoki Izawa, Yu Sunakawa.

• Association between tumor shrinkage and survival in BRAF-mutated metastatic colorectal cancer (mCRC) treated with encorafenib combination therapy: The BEETS trial (JACCRO CC-18).
  Y. Sunakawa, D. Kotani, T. Denda, C. Inagaki, T. Kashiwada, Y. Horita, A. Sugaya, Y. Suwa, T. Ohta, S. Kondo, K. Oshima, M. Shiozawa, C. Tanaka, T. Kudo, Y. Mori, E. Inoue, W. Ichikawa, M. Fujii.

• Overall survival benefit of doublet versus triplet BRAF inhibitor–based therapy: Insights from the BEETS study (JACCRO CC-18).
  C. Inagaki, R. Matoba, H. Lijuma, D. Kotani, T. Denda, T. Kashiwada, Y. Horita, A. Sugaya, Y. Suwa, T. Ohta, S. Kondo, K. Oshima, M. Shiozawa, C. Tanaka, T. Kudo, Y. Mori, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa.

• Efficacy of capeOX plus nivolumab in patients with early relapsed HER2-negative gastric cancer: Results from the phase II JACCRO GC-11 (FirSTAR) trial.
  H. Arai, H. Takahashi, M.N. Tsuda, O. Muto, H. Tazawa, A. Takeno, Y. Nakahara, T. Kashiwada, H. Hara, S. Yuki, S. Kagawa, M. Terashima, E. Baba, N. Matsuhashi, K. Muro, T. Yamaguchi, E. Inoue, Y. Sunakawa, W. Ichikawa, M. Fujii.

• Prognostic impact of CSF1R expression in gastric cancer in the MONSTAR-SCREEN-2: An international collaborative study between United States and Japan.
  K. Seguchi, T. Hashimoto, S. Kadowaki, A. Makiyama, M. Ueno, N. Takahashi, S. Boku, T. Kudo, E. Oki, F. Nagashima, K. Yamazaki, K. Ohtsubo, S. Yuki, Y. Sunakawa, T. Fujisawa, H. Bando, S. Algaze, . Millstein, H.J. Lenz, T. Yoshino.

• Clinical significance of MYC and cell cycle axis in metastatic colorectal cancer: A SCRUM-Japan GOZILA substudy.
  H. Osumi, E. Shinozaki, Y. Nakamura, T. Esaki, H. Yasui, H. Taniguchi, H. Satake, Y. Sunakawa, Y. Komatsu, Y. Kagawa, T. Denda, M. Shiozawa, T. Satoh, T. Nishina, T. Yamaguchi, N. Takahashi, T. Kato, S. Maeda, H. Bando, T. Yoshino.

• Association between progression pattern after first-line therapy and outcomes in metastatic pancreatic cancer: An exploratory analysis of JCOG1611.
  S. Kobayashi, T. Terashima, H. Imaoka, Y. Ishikawa, Y. Sano, A. Ohba, K. Nakachi, T. Okusaka, T. Yamashita, M. Ikeda, I. Yasuda, H. Miwa, S. Shimizu, K. Umemoto, H. Nagano, T. Honda, S. Kataoka, M. Ozaka, J. Furuse, M. Ueno.

2025年度

2025.04 AACR

• Mutational Profiles of Pancreatic Cancer Patients from Eastern.
  Jacquelyn Reuther1, Taro Shibuki2, Megan Hawley1, Hideaki Bando2, Keir Violaceae1, Makoto Ueno3, Kenji Ikezawa4, Takuji Okusaka5, Teiichi Sugiura6, Keiko Kamei7, Yoshito Komatsu8, Michiaki Unno9, Hiroki Yukami10.

2025.06 ASCO

• An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19).
  Yu Sunakawa, Chiaki Inagaki, Satoshi Yuki, Kota Ouchi, Toshihiro Kudo, Hironaga Satake, Tomomi Kashiwada, Eisuke Inoue, Ryo Matoba, Wataru Ichikawa.

• Survival impact of NeoRAS wild-type metastatic colorectal cancer: A SCRUM-Japan GOZILA substudy.
  Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Toshifumi Yamaguchi, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino.

• Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials.
  Yoshinori Kagawa, Hiroya Taniguchi, Daisuke Kotani, Tadayoshi Hashimoto, Hideaki Bando, Tetsuya Hamaguchi, Akiyoshi Kanazawa, Takeshi Kato, Koji Ando, Hisateru Yasui, Eiji Shinozaki, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Satoshi Yuki, Yoshiaki Nakamura, Masashi Wakabayashi, Hiromichi Nakajima, Takashi Ohta, Takayuki Yoshino.

• Genomic landscape and biomarker analyses utilizing circulating-tumor DNA in advanced esophageal squamous cell carcinoma: Sub-analysis of SCRUM-MONSTAR GOZILA.
  Yuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, Hiroya Taniguchi, Yu Sunakawa, Yoshito Komatsu, Naoki Takahashi, Yuta Sato, Kensei Yamaguchi, Tomohiro Nishina, Tomonori Nakanoko, Shogen Boku, Taroh Satoh, Hisateru Yasui, Taito Esaki, Mitsuho Imai, Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino.

2025.07 ESMO-GI

• Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC).
  Kensei Yamaguchi, Atsuo Takashima, Shogen Boku, Tadamichi Denda, Akihito Kawazoe, Toshihiro Kudo, Hisateru Yasui, Hiroshi Matsuoka, akeshi Kato, Yujiro Nishizawa, Nozomu Machida, Hiroki Hara, Yu Sunakawa, Yosuke Horita, Mitsuru Yokota, Yoshito Komatsu, Toshifumi Yamaguchi, Masaya Yano, Takayuki Yoshino.
• Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18).
  Chiaki Inagaki, Ryo Matoba, Eisuke Inoue, Daisuke Kotani, Tadamichi Denda, Tomomi Kashiwada, Yoshiaki Mihara, Akinori Sugaya, Yusuke Suwa, Takashi Ohta, Hidekazu Kuramochi, Kotoe Oshima, Chihiro Tanaka, Toshihiro Kudo, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Kei Muro, Wataru Ichikawa, Yu Sunakawa.
• Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS/BRAF wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).
  Yu Sunakawa, Manabu Shiozawa, Yoshiaki Shindo, Yasuhide Ishikawa, Mutsumi Fukunaga, Takuya Tokunaga, Satoshi Yuki, Naotoshi Sugimoto, Masahito Kotaka, Kiyoshi Ishigure, Eiji Oki, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Tamotsu Sagawa, Mitsugu Kochi, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji.

2025.10 ESMO

• Encorafenib, cetuximab, plus binimetinib combination therapy for BRAF-mutated metastatic colorectal cancer (mCRC) with prognostic factors: The BEETS trial (JACCRO CC-18).
  Y. Sunakawa, E. Inoue, D. Kotani, T. Denda, C. Inagaki, T. Kashiwada, Y. Horita, A. Sugaya, Y. Suwa, T. Ohta, H. Kuramochi, K. Oshima, M. Shiozawa, C. Tanaka, Y. Mori, S. Yuki, A. Tsuji, K. Muro, W. Ichikawa, M. Fujii.
• Asian and rest of world (RoW) subgroup analysis of sotorasib plus panitumumab for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC) in the CodeBreaK 300 and CodeBreaK 101 trials.
  Y. Kuboki, T. Esaki, J.B. Ahn, Y. Sunakawa, K. Yamaguchi, M. Tsuda, K. Yamazaki, T. Nishina, T. Satoh, H. Hara, K. Yeh, J. Hippenmeyer, J. Chao, C. Nduka, Q. Tran, T. Masuishi, T.W. Kim.
• Clinical features of Neo BRAF wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
  H. Osumi, E. Shinozaki, Y. Nakamura, T. Esaki, H. Yasui, H. Taniguchi, H. Satake, Y. Sunakawa, . Komatsu, Y. Kagawa, T. Denda, M. Shiozawa, T. Satoh, . Nishina, T. Yamaguchi, N. Takahashi, T. Kato, H. Bando, K. Yamaguchi, T. Yoshino.
• A phase II basket study of necitumumab for EGFR amplification–positive metastatic solid tumors: WJOG15021M.
  S. Mitani, T. Masuishi, M. Nomura, K. Hirata, H. Bando, Y. Sunakawa, K. Nakanishi, N. Takahashi, Y. Miura, S. Hamauchi, T. Esaki, W. Okamoto, C. Kudo, Y. Nakamura, H. Hayashi, M. Ando, T. Tsuruta, Y. Kuwatsuka, K. Muro, Y. Kodera.
• Impact of conversion surgery (CS) on the prognostic value of depth of response (DpR) in patients with metastatic colorectal cancer (mCRC): A post-hoc analysis of the DEEPER trial (JACCRO CC-13).
  Y. Mihara, K. Pak, Y. Sunakawa, A. Makiyama, H. Satake, M. Shiozawa, T. Kawai, H. Ota, H. Yasui, T. Yabuno, M. Tei, M. Kochi, D. Manaka, T. Yamaguchi, M. Matsuura, H. Katsuya, A. Tsuji, M. Fujii, W. Ichikawa.

2025.12 ESMO-Asia

• Comprehensive biomarker study of zolbetuximab plus CapeOX or SOX to identify predictors of efficacy and resistance mechanisms in patients with HER2-negative, CLDN18.2-positive gastric or gastro-oesophageal junction cancer (JACCRO GC-12AR).
  Yohei Kubota, Genki Usui, Ryohei Kawabata, Yuya Yoshida, Chiaki Inagaki, Toshifumi Yamaguchi, Kazuaki Harada, Satoshi Yuki, Hisato Kawakami, Wataru Ichikawa, Masashi Fujii, Bernd Bodenmiller, Yu Sunakawa (Kawasaki, JP).

2026.1 ASCO-GI

• JAGUAR (JACCRO PM-01): A prospective study to evaluate the clinical utility of serial comprehensive genomic profiling testing using circulating tumor DNA in patients with metastatic colorectal cancer.
  Yu Sunakawa, Toshiki Masuishi, Hiroyuki Takeda, Sho Umegaki, Kyongsun Pak, Satoshi Yuki, Yuki Kasahara, Tadamichi Denda, Naotoshi Sugimoto, Yoshinaga Okugawa, Yosuke Kumekawa, Tomohiro Nishina, Taito Esaki, Kei Muro, Wataru Ichikawa, and Soichiro Ishihara.
• A phase Ⅱstudy of re-introduction of gemcitabine pluscisplatin in combination with durvalumab after durvalumab maintenance therapy in patients with unresectable or recurrent biliary tract cancer (PRIDE study).
  Hiroyuki Takeda, Kumiko Umemoto, Ryoji Takada, Tomoyuki Satake, Shunsuke Onoue, Satoshi Shimizu, Hiroshi Nalkase, Kenro Hirata, Kasuhiko Shioji, Kazuyuki Matsumoto, Ayako Hata, Kenichiro Tanabe, Makoto Ueno, Junji Furuse, Yu Sunakawa.
• Comparative effectiveness of trastuzumab deruxtecan versus real-world treatment in HER2-amplified advanced solid tumors detected by cell-free DNA: An exploratory analysis of the HERALD trial and GOZILA study.
  Taro Mizuno, Hiroya Taniguchi, Taroh Satoh, Hideaki Bando, Shigenori Kadowaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Taito Esaki, Ken Kato, Satoshi Yuki, Takeshi Kato, Kensei Yamaguchi, Makoto Ueno, Yosuke Horita, Akihiro Sato, Masataka Yagisawa, Takayuki Yoshino, and Yoshiaki Nakamura.
• A phase 2 randomized study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with standard of care (SOC) in patients with metastatic colorectal cancer.
  Ardaman Shergill, Michael Cecchini, Gerald W. Prager, Stacey A. Cohen, Akihito Kawazoe, Stephanie Wu, Kunal Desai, Martha Raluca Neagu Aristide, Apurvasena Parikh, Athanasios Vasilopoulos, Yunxia Sui, Yu Sunakawa.

2024年度

2024.06 ESMO-GI

• Association of gastric background mucosa status with the efficacy of immune checkpoint inhibitors in patients with unresectable advanced gastric cancer.
  Yuma Kamijo, Yusuke Nagata, Hiroshi Suzuki, Hideo Kunimoto, Ayako Seki, Yasushi Sekino, Masahiro Sakon, Hiroyasu Ushimaru, Etsuo Hara.
• Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)Y.
  Sunakawa, M. Shiozawa, T. Kawai, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, M. Matsuura, Y. Shinohara, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji.
• Blood-based oxidative phosphorylation-related gene signature and their SNPs as novel prognostic biomarkers for gastric cancer patients treated with nivolumab.
  C. Inagaki, R. Matoba, H. Lijuma, J. Hihara, H. Yasui, N. Takegawa, T. Suzuki, A. Makiyama, H. Yabusaki, J. Matsuyama, M. Takahashi, Y. Kito, Y. Akamaru, A. Ishiguro, R. Kawabata, Y. Sakamoto, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa.
• A phase II study of mFOLFOX6 plus nivolumab as initial therapy for patients with advanced esophageal squamous-cell cancer: FLONTALE trial.
  Y. KUBOTA, S. Ueyama, Y. Yamamoto, Y. Amanuma, M. Furuta, S. Sato, T. Tsushima, T. Moriwaki, K. Tanabe, Y. Sunakawa.
• Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR.
  H. Takeda, R. Kawabata, A. Ishiguro, S. Nishina, M. Takahashi, S. Suzuki, T. Suzuki, J. Matsuyama, Y. Otsuki, Y. Akamaru, N. Takegawa, T. Nomura, Y. Kito, H. Yabusaki, Y. Negoro, A. Makiyama, M. Nakamura, M. Takahashi, Y. Sunakawa.

2024.06 ASCO

• Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
  Hiroaki Kanemura, JUNKO TANIZAKI, Koji Matsumoto, Toshiki Masuishi, Taichi Isobe, Hiroaki Kodama, Toshio Shimizu, Yu Sunakawa, Yasutaka Chiba, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hidetoshi Hayashi.
• Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).
  Daisuke Kotani, Hideaki Bando, Hiroya Taniguchi, Toshiki Masuishi, Taito Esaki, Yu Sunakawa, Yoshito Komatsu, Eiji Shinozaki, Taroh Satoh, Tomohiro Nishina, Yoshiaki Nakamura, Yuichi Mikamoto, Masashi Wakabayashi, Akihiro Sato, Shogo Nomura, Hiromichi Ebi, Takayuki Yoshino.
• A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2.
  Koji Ando, Yoshinori Kagawa, Mamoru Uemura, Jun Watanabe, Masaaki Miyo, Yasunori Emi, Nobuhisa Matsuhashi, Naoki Izawa, Osamu Muto, Tatsuya Kinjo, Yujiro Nishizawa, Tsuyoshi Hata, Yusuke Suwa, Takuya Honboh, Jesse Yu Tajima, Yu Sunakawa, Koji Oba, Ichiro Takemasa, Eiji Oki.
• Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.
  Akira Ooki, Kei Muro, Kazumi Nishino, Hisato Kawakami, Hitoshi Ojima, Takashi Kojima, Yoshihiro Tanaka, Kazuo Koyanagi, Nozomu Machida, Susumu Eguchi, Koichi Suyama, Yasutaka Watanabe, Naoki Izawa, Katsunori Iijima, Hiroshi Hirai, Michael Jon Chisamore, and Ken Kato.

2024.09 KINGCA 2024 Korea International Gastric Cancer

• Insight into co-expression biomarker in gastric cancer.
  Yohei Kubota.

2024.09 ESMO

• Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): subgroup analyses of WJOG9216G (RECAST).
  K Shiraishi, Y Kito, H Shoji, T Yamada, T Tsushima, S Mitani, H Yasui, H Hara, K Shimozaki, T Esaki, Y Shinohara, T Tsuzuki, S Kajiura, N Izawa, K Murata, K Yoshimura, H Kawakami, S Hironaka, K Yamazaki, K Muro.

2024.09 ESMO Congress 2024

• Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody.
  K. Sugiyama, H. Yasui, M. Nakamura, T. Sagawa, T. Kawai, K. Kataoka, D. Manaka, N. Akazawa, T. Okuno, T. Shimura, M. Shiozawa, Y. Sunakawa, H. Ota, M. Kotaka, H. Okuyama, Y. Okita, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji.

2025.01 ASCO-GI

• Encorafenib and cetuximab with/without binimetinib therapies for patients with BRAF-mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18).
  Yu Sunakawa, Eisuke Inoue, Daisuke Kotani, Tadamichi Denda, Chiaki Inagaki, Tomomi Kashiwada, Yosuke Horita, Akinori Sugaya, Yusuke Suwa, Takashi Ohta, Hidekazu Kuramochi, Kotoe Oshima, Manabu Shiozawa, Satoshi Yuki, Akihito Tsuji, Kei Muro, Wataru Ichikawa, Masashi Fujii.
• A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301).
  Tae Won Kim, Timothy Price, Julieta Grasselli, John Strickler, Toshiki Masuishi, Gin Wai Kwok, Suayib Yalcin, Cynthia Obiozor, Emily Chan, Priya Gokani, Yu Sunakawa.
• Association between ctDNA levels, timing of blood collection, and overall survival in metastatic colorectal cancer.
  Akinori Kobayashi, Yoshiaki Nakamura, Tadayoshi Hashimoto, Hiroya Taniguchi, Yoshito Komatsu, Taito Esaki, Yu Sunakawa, Kensei Yamaguchi, Takeshi Kato, Manabu Shiozawa, Naoki Takahashi, Takashi Ohta, Tadamichi Denda, Hironaga Satake, Tomohiro Nishina, Hisateru Yasui, Hideaki Bando, Takayuki Yoshino.
• Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).
  Akihito Tsuji, Yu Sunakawa, Manabu Shiozawa, Takashi Kawai, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Masato Matsuura, Hiroo Katsuya, Akitaka Makiyama, Masakazu Ikenaga, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.
• Prediction of relapse-free survival in stage III gastric cancer patients treated with postoperative adjuvant chemotherapy: Random survival forest analysis from the START-2 trial.
  Hiroki Sato, Wataru Ichikawa, Kazuhiro Yoshida, Yasuhiro Kodera, Yoshihiro Kakeji, Mitsugu Kochi, Masazumi Takahashi, Akinori Takagane, Kiyoshi Ishigure, Masahide Kaji, Narutoshi Nagao, Makoto Yamada, Akiharu Ishiyama, Takanobu Yamada, Norimasa Fukushima, Toshifumi Yamaguchi, Masahiro Takeuchi, Yu Sunakawa, Masashi Fujii, Takeshi Sano.
• The prognostic impact of SLFN11 gene expression in metastatic colorectal cancer (mCRC).
  Arai H, Yang Y, Milllstein J, Ashouri K, Ou FS, Innocenti F, Battaglin F, Algaze S, Soni S, Zhang Wm Venook AP, Lenz HJ.

論文業績（和文）

2026年度

《その他》

1. RAS野生型大腸癌に対する治療の最適化

• 消化器内科, 38(7)：18-24.
• 武田弘幸

2. がんの初期対応と治療の基本戦略

• レジデントノート, 28（4）：658-664.
• 小川和起, 武田弘幸, 砂川優

3. 治療中の支持療法・副作用マネジメントと緊急症状の対応

• レジデントノート, 28(7):1203-1211.
• 八木智也、伊澤直樹、砂川優

2024年度

《原著・総説・解説》

1. 進行もしくは再発膵癌におけるUGT1A1遺伝子多型とイリノテカンとの関連性

• 胆と膵, 45(11)：1641-1645.
• 梅本久美子

2. 大腸がんにおける免疫療法と分子標的治療の併用

• がん分子標的・免疫治療.
• 永田祐介

3. FOLFOXIRI 療法

• 外科医のための大腸癌薬物療法ガイドブック, 84-89.
• 永田祐介

4. 切除可能進行胃癌に対する術前DOS（Docetaxel＋Oxaliplatin＋S-1）療法＋手術＋S-1術後補助化学療法 vs. 手術＋S-1術後補助化学療法の第III相試験（PRODIGY試験）における全生存期間のアップデート

• 消化器癌治療の広場.
• 久保田　洋平、伊澤　直樹

5. 切除不能な進行・再発胃癌に対する薬物療法の新展開

• 癌と化学療法.
• 久保田　洋平、砂川　優

6. 腸内細菌と胃癌

• 癌と化学療法.
• 砂川　優

論文業績（英文）

2026年度

《原著・総説・解説》

1. Metabolic and functional pathways of gut microbiota in patients with gastric cancer.

• Scietific Reports. 2026 Apr 10;16(1):16940.
• Ryo Matoba, Hiroshi Iijima, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masaki Aizawa, Jin Matsuyama, Masazumi Takahashi, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Hiroyuki Okuda, Junji Kawada, Takashi Yoshioka, Hisato Kawakami, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.

2. Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).

• European Journal of Cancer. 2026 May 2:238:116684.
• Hiroaki Kanemura, Junko Tanizaki, Koji Matsumoto, Toshiki Masuishi, Taichi Isobe, Hirotsugu Kenmotsu, Yu Sunakawa, Toshio Shimizu, Yasutaka Chiba, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hidetoshi Hayashi.

3. Diagnostic performance of droplet digital PCR for KRAS mutation analysis in pancreatic cancer cytology specimens.

• Journal of Gastroenterology. 2026 May 23.
• Kumiko Umemoto, Kazunari Nakahara, Nobuyuki Ohike, Yusuke Satta, Akihiro Sekine, Yosuke Igarashi, Yusuke Nagata, Yohei Kubota, Hiroyuki Takeda, Yoshiki Horie, Hiroyuki Arai, Naoki Izawa, Hayato Hiraki, Tomoko Norose, Junki Koike, Ryo Matoba, Satoshi Nishizuka, Keisuke Tateishi, Yu Sunakawa.

4. Clinical Implications of Polyploid Giant Cancer Cells in Solid Tumors: Biology, Diagnosis, and Therapeutic Considerations.

• Cancers. 2026 Jun 1;18(11):1818.
• Hiroshi Imaoka, Masafumi Ikeda, Masashi Wakabayashi, Kumiko Umemoto, Tomoyuki Satake, Yu Sunakawa, Hideki Ueno, Kazuo Hara, Fumio Nagashima, Shigeki Kataoka, Terumasa Hisano, Yuko Suzuki, Akinori Asagi, Kazuhiko Shioji, Kotoe Oshima, Kunihiro Tsuji, Kazuyoshi Ohkawa, Ikuya Miki, Yasuyuki Kawamoto, Taro Yamashita, Makoto Ueno, Yujiro Kawakami, Hiroaki Nagano, Hiroyuki Okuyama, Atsushi Naganuma, Rei Suzuki, Junji Furuse.

5. Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study.

• Therapeutic Advances in Medical Oncology. 2026 Aug 6:18:17588359261476046.
• Hiroko Hasegawa, Rin Inamoto, Keiji Sugiyama, Naoki Izawa, Seiichiro Mitani, Takeshi Kawakami, Satoshi Yuki, Hidekazu Hirano, Saori Mishima, Tetsutaro Hamano, Toshiki Masuishi.

6. Chemotherapy After Colonic Stent in Patients With Unresectable Obstructive Colorectal Cancer: A Retrospective Multicenter Observational Study.

• Endoscopy International Open. 2026 Jul 30:14:a29191621.
• Akihisa Matsuda, 1, Norihiro Hanabata, Yorinobu Sumida, Naohiko Harada, Shinsuke Matsunaga, Gota Fujisawa, Koichi Miyahara, Akinari Takao, Hiroyuki Hisai, Toshio Kuwai, Shuji Saito, Shungo Endo, Yu Sunakawa, Takeshi Yamada, Hiroshi Yoshida, Hiroyuki Isayama, Yoshihisa Saida.

7. Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer.

• BMC Cancer. 2026 Jul 17.Online ahead of print.
• Yuki S, Kawakami H, Harada K, Kubota Y, Pak K, Kakeji Y, Terashima M, Baba E, Muro K, Sunakawa Y, Ichikawa W, Fujii M.

8. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

• Journal of Clinical Oncology. 2026 Jul 1:JCO2503128. Online ahead of print.
• James M Cleary, Christoph Springfeld, Dirk Arnold, Antoine Hollebecque, Olumide Gbolahan, Misako Nagasaka, Salvatore Siena, Frans Opdam, Yu Sunakawa, Philippe A Cassier, Gaurav Trikha, Eelke H Gort, Vaia Florou, Richard Greil, Paul F La Porte , Pritesh J Gandhi, Fiona Garner, Ernesto Wasserman, Shola Adeyemi, Alison M Schram.

9. Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial.

• Targeted Oncology. 2026 Jul;21(4):549-557.
• Yu Sunakawa, Hisateru Yasui, Manabu Shiozawa, Hiroyuki Takeda, Naoya Akazawa, Tamotsu Sagawa, Kazuhiro Shiraishi, Takahisa Kyogoku, Takashi Mine, Yasuhiro Yuasa, Takanori Watanabe, Tatsuya Kinjo, Yoshihiro Okita, Hiroyuki Okuyama, Satoshi Yuki, Koki Miyakawa, Ayana Kobara, Shoko Yanaka, Yukiko Abe, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji.

10. Bridging the distance in precision oncology: a nationwide survey on institutional perspectives toward telemedicine and decentralized trials in Japan.

• International journal of clinical oncology. 2026 Jul;31(7):1275-1282.
• Hiroya Taniguchi, Takeshi Kawakami, Hironaga Satake, Yuko Tamura, Takuma Matsunaga, Yu Sunakawa.

11. Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/ BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

• Journal of Clinical Oncology. 2026 Aug.
• Yu Sunakawa, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji.

12. Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer.

• iScience. 2026 Aug 13;29(9):117112.
• Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Toshifumi Yamaguchi, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino.



《症例報告》

1. Orbital Metastasis of Pancreatic Cancer Not Detected on MRI at the Time of Clinical Presentation.

• Cancer Diagnosis & Prognosis. 2026 Jul 1;6(4):820-824.
• Takashi Ogura, Yu Sunakawa.

2. SMARCB1/INI1-deficient Undifferentiated Carcinoma Presenting as Cancer of Unknown Primary with Massive Hepatic Involvement: Transient Response to FOLFOX plus Nivolumab.

• Internal Medicine. 2026 Aug 8. Online ahead of print.
• Yosuke Saito, Hiroyuki Takeda, Ayaka Yamasaki, Tomoko Norose, Hiroyuki Arai, Nobuyuki Ohike, Shuhei Suzuki, Yuta Yamada, Koshi Takahashi, Ryosuke Kumanishi, Tadahisa Fukui, Masanobu Takahashi.



2025年度

《原著・総説・解説》

1. Prospective Cohort Study of Trastuzumab Biosimilar CT-P6 in HER2-Positive Gastric Cancer: Japanese Real-World Outcomes.

• Oncology and Therapy. 2025 Jun;13(2):485-503.
• Hiroya Taniguchi, Kiyohiro Nishikawa, Tatsuo Haneji, Naoki Izawa, Hiroshi Imamura, Hironori Yamaguchi.

2. A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.

• Future Oncology. 2025 Jul;21(17):2135-2141.
• Munehiro Wakabayashi, Toshiki Masuishi, Takatsugu Ogata, Fumiyasu Hanamura, Mitsuhiro Furuta, Yoshiyuki Yamamoto, Kentaro Kawakami, Hidekazu Hirano, Yosuke Kito, Naoki Izawa, Naoki Takahashi, Toshihiko Matsumoto, Hisato Kawakami, Takayuki Ando, Keiko Minashi, Chiho Kudo, Kenichi Yoshimura, Kei Muro.

3. An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

• Gastric Cancer. 2025 Jul 9.
• Kadowaki S, Otsuka T, Minashi K, Nishina S, Yabusaki H, Inagaki C, Nishina T, Yasui H, Matsuoka H, Machida N, Tsuda M, Nagashima F, Hosaka H, Matsubara J, Arai H, Ida S, Kimijima Y, Matsuda Y, Muto M, Muro K.

4. Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G).

• International jornal of cancer. 2025 Dec 15;157(12):2577-2588.
• Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, Hidekazu Hirano, Saori Mishima, Hiroyuki Takahashi, Tomoyuki Otsuka, Kenta Kawasaki, Takeshi Kawakami, Kazuhiro Yanagihara, Takaya Shimura, Masato Komoda, Kozue Murayama, Keiko Minashi, Yoshiyuki Yamamoto, Yudai Shinohara, Shinichi Nishina, Nobuyuki Musha, Kyoko Kato, Kentaro Kawakami, Katsunori Shinozaki, Kenji Tsuchihashi, Takayuki Ando, Yosuke Kito, Akitaka Makiyama, Seiichiro Mitani, Kaori Hino, Naoki Izawa, Isao Oze, Kei Muro.

5. Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR.

• ESMO Open. 2025 May;10(5):105076.
• Ouchi K, Sunakawa Y, Tsuji A, Shiozawa M, Kawai T, Yasui H, Ota H, Kochi M, Manaka D, Ohori H, Miyake T, Yamaguchi T, Matsuura M, Sagawa T, Makiyama A, Takeuchi M, Ichikawa W, Fujii M, Ishioka C.

6. Real-World Genomic Landscape of Gastrointestinal Cancers in Asia and the Middle East Using Comprehensive Circulating Tumor DNA Next-Generation Sequencing.

• Oncol Res Treat. 2025 May;5:1-17.
• Muto M, Sunakawa Y, Sandhir N, Liang YH, Dawood S, Rohatgi N, Bahl A, Olsen S.

7. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.

• JCO Precis Oncol.(JCO Precision oncology). 2025 Apr:9:e2400283.
• Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, Matsubara N, Iwata H, Naito Y, Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M, Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T, Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M, Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR, Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, Yoshino T.

8. Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).

• J Journal of Gastroenterology. 2025 Sep 6.
• Satoshi Kobayashi, Kohei Nakachi, Kouji Yamamoto, Makoto Ueno, Yuta Maruki, Kenji Ikezawa, Takeshi Terashima, Satoshi Shimizu, Kotoe Oshima, Kunihiro Tsuji, Yoshiharu Masaki, Hidetaka Tsumura, Taro Shibuki, Masato Ozaka, Naohiro Okano, Yukiyasu Okamura, Kumiko Umemoto, Tatsunori Satoh, Yasushi Kojima, Kazuhiko Shioji, Hiroko Nebiki, Toshifumi Doi, Atsushi Naganuma, Shigeki Kataoka, Emiri Kita, Hiroyuki Asama, Kaoru Tsuchiya, Michiaki Unno, Reiko Ashida, Kazuyuki Matsumoto, Izumi Ohno, Takao Itoi, Yuji Negoro, Yasunari Sakamoto, Shiho Arima, Akinori Asagi, Hiroyuki Okuyama, Yoshito Komatsu, Noritoshi Kobayashi, Hiroaki Nagano , Junji Furuse.

9. A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study).

• J ESMO Open. 2025 Sep 6;10(9):105571.
• M. Wakabayashi, H. Taniguchi, A. Makiyama, Y. Sunakawa, H. Takeda, K. Arimizu, Y. Okumura, C. Inagaki, S. Mitani, T. Kudo, S. Yuki, N. Akazawa, C. Kudo, K. Mori, T. Matsuda, K. Muro.

10. Circulating Tumor DNA Profiling Reveals Genomic Evolution in Recurrent Gastric or Gastroesophageal Junction Cancer.

• J Molecular Diagnosis & Therapy. 2025 Sep;29:839–847.
• Ryohei Kawabata, Hiroyuki Takeda, Atsushi Ishiguro, Shinichi Nishina, Masazumi Takahashi, Shuhei Suzuki, Takahisa Suzuki, Jin Matsuyama, Yasufumi Otsuki, Yusuke Akamaru, Naoki Takegawa, Takashi Nomura, Yosuke Kito, Hiroshi Yabusaki, Yuji Negoro, Akitaka Makiyama, Masato Nakamura, Masaki Takahashi & Yu Sunakawa.

11. Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

• Cancer Research Communications. 2025 May 1;5(5):857-870.
• Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai, Satoshi Horasawa, Ayumu Yoshikawa, Takao Fujisawa, Shigenori Kadowaki, Ken Kato, Makoto Ueno, Eiji Oki, Yoshito Komatsu, Tatsuyuki Chiyoda, Yosuke Horita, Hisateru Yasui, Tadamichi Denda, Hironaga Satake, Taito Esaki, Taroh Satoh, Naoki Takahashi, Kentaro Yamazaki, Nobuhisa Matsuhashi, Tomohiro Nishina, Hiroyuki Takeda, Koushiro Ohtsubo, Takashi Ohta, Akihito Tsuji, Masahiro Goto, Takeshi Kato, Hideaki Bando, Katsuya Tsuchihara, Yoshiaki Nakamura, Takayuki Yoshino.

12. Efficacy of Adding Immune Checkpoint Inhibitors to Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

• Cancers. 2025 jul;17(15):2538.
• Fumihiko Ando, Akihisa Matsuda, Yuji Miyamoto, Yu Sunakawa, Tomoko Asatsuma-Okumura, Yoshiko Iwai, Hiroshi Yoshida.

13. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.

• International journal of clinical oncology. 2025 Oct;30(10):2043-2052.
• Daisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Hisato Kawakami, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Cathy Eng, Stacey Ukrainskyj, Rajash Pallai, Shivani Nanda, Zhao Yang, William Schelman, Marek Kania, Taroh Satoh.

14. Efficacy and safety of FOLFOX for Japanese patients with advanced biliary tract cancer as second-line or later chemotherapy (JON2107-B study).

• International Journal of Clinical Oncology. 2025 Oct 19.
• Takeshi Terashima, Chigusa Morizane, Akihiko Chida, Akiko Todaka, Kumiko Umemoto, Yujiro Kawakami, Tatsuya Yamashita, Makoto Ueno, Junji Furuse, Hiroaki Nagano.

15. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched analysis.

• Pancreatology. 2025 Sep;25(6):950-958.
• Naohiro Okano, KentaroSakamaki,TakafumiMie, KazuoWatanabe, SatoshiKobayashi, AkikoTodaka, YukoSuzuki, HidetoshiKitamura, KazunariTanaka, KeiNakagawa,KeikoKamei, KumikoUmemotom, NobuakiAzemoto, YasuyukiKawamoto, HiroakiYanagimoto, KunihiroTsuji, HiroshiImaoka, TakeshiTerashima, ChigusaMorizane, MasafumiIkeda, MasatoOzaka, MakotoUeno, JunjiFuruseae, Japan Observational Study Committee of Hepatobiliary and Pancreatic Oncology (JOSC-HBP).

16. A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701).

• ESMO Open. 2025 Oct;10(11):105839.
• Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Sunakawa Y, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Sakamoto Y, Kuramoto N, Miki I, Ichiki H, Nakamura Y, Sharma G, Skrzypczak S, Schultz E, Kingsford C, Ohtsu A, Yoshino T.

17. Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001).

• Neuroendocrinology. 2025 Sep 26 (2026) 116 (1): 32–42.
• Hiroyuki Okuyama, Taro Shibuki, Naohiro Okano, Takuro Mizukami, Hiroaki Yanagimoto, Mao Okada, Emiri Kita, Noritoshi Kobayashi, Satoshi Kobayashi, Takaaki Furukawa, Hiroyuki Asama, Hidetaka Tsumura, Ken Kamata, Kumiko Umemoto, Yasuo Hamamoto, Yuko Suzuki, Shigeru Horiguchi, Atsushi Naganuma, Akinori Asagi, Kunihiro Tsuji, Ryoji Takada, Kazuhito Kawata, Motohiro Kojima, Hiroshi Imaoka, Takeshi Terashima, Masato Ozaka, Makoto Ueno, Masafumi Ikeda.

18. Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trial.

• Esophagus. 2026 Jan;23(1):120-130.
• Chikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, Yasuo Hamamoto, Ayumu Hosokawa, Takashi Kojima, Hiroki Hara, Takako Yoshii, Hirofumi Fujii, Hironori Yamaguchi, Takako Eguchi Nakajima, Naoki Izawa, Takayuki Ando, Motoo Nomura, Keishi Yamashita, Shogo Kawakami, Hiromichi Ishiyama, Yusuke Inoue, Yasutoshi Sakamoto, Hideki Ishikawa, Manabu Muto, Makoto Tahara, Wasaburo Koizumi.

19. Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: a secondary analysis of a randomized clinical trial.

• The Oncologist. 2026 Feb 18;31(4):oyag047.
• Takahiro Higashibata, Takaomi Kessoku, Shinya Kajiura, Mami Hirakawa, Shunsuke Oyamada, Keisuke Ariyoshi, Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Hiroka Nagaoka, Yasuyuki Takashima, Kosuke Doki, Bryan J. Mathis, Kosuke Tanaka, Akiko Fuyuk, Atsushi Nakajima, Yo Ishihara, Ryuji Hayashi, Takayuki Ando, Yuko Kobayashi, Naoki Izawa, Yoshiki Horie, Tatsuya Morita, Jun Hamano.

20. Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

• European Journal of Cancer. 2026 May 2:238:116688.
• Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, Takeshi Yamada, Takahiro Tsushima, Seiichiro Mitani, Kazuhiro Shiraishi, Hisateru Yasui, Hiroki Hara, Kenro Hirata, Taito Esaki, Yudai Shinohara, Takao Tsuzuki, Shinya Kajiura, Toshiki Masuishi, Naoki Izawa, Eishi Baba, Kohei Murata, Naoya Akazawa, Yozo Suzuki, Kei Muro.

21. Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

• JCO Precision Oncology. 2026 Mar;10(3):e2500971.
• Authors: Yuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, Hiroya Taniguchi, Yu Sunakawa, Yoshito Komatsu, Naoki Takahashi, Yuta Sato, Kensei Yamaguchi, Tomohiro Nishina, Tomonori Nakanoko, Shogen Boku, Taroh Satoh, Hisateru Yasui, Taito Esaki, Mitsuho Imai, Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino.

22. Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.

• The Oncologist. 2026 Mar 9;31(4):oyag068.
• Daisuke Kotani, Eisuke Inoue, Tadamichi Denda, Chiaki Inagaki, Tomomi Kashiwada, Yoshiaki Mihara, Akinori Sugaya, Yusuke Suwa, Takashi Ohta, Hidekazu Kuramochi, Kotoe Oshima, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.



《症例報告》

1. A Case of Pancreatic Ductal Adenocarcinoma in PRSS1-Associated Hereditary Pancreatitis in the Absence of High-Grade PanIN: Suggestive of Chromothripsis-Like Tumor Evolution.

• Pathol Int. 2025 Oct 14.
• Norose T, Ohike N, Nakahara K, Tateishi K, Kobayashi S, Arai H, Sunakawa Y, Sugiura Y, Koizumi H, Koike J.



《その他》

1. A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia.

• ESMO Gastrointestinal Oncology. 2026 Feb;Volume 11, 100310.
• Y. Nagata, H. Arai, N. Izawa, C. Inagaki, A. Sugaya, K. Hirata, T. Tsushima, T. Moriwaki, T. Masuishi, Y. Nagatani, K. Harada, M. Taguri, Y. Sunakawa.

2024年度

《原著・総説・解説》

1. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).

• Cancer Medicine. 2024 Apr;13(7):e7107.
• Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE.

2. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.

• Esophagus.2024 Apr;21(2):102-110.
• Hara H, Satoh T, Kojima T, Tsushima T, Sunakawa Y, Okada M, Ding N, Wu H, Li L, Yu T, Barnes G, Kato K.

3. BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.

• ESMO Gastrointestinal Oncology.2024 June; Volume 4, 100066.
• Yuki Matsubara, Hideaki Bando, Daisuke Kotani, Yoshinori Kagawa, Kazuaki Harada, Hiroki Osumi, Naoki Izawa, Takeshi Kawakami, Shogen Boku, Toshihiko Matsumoto, Masashi Wakabayashi, Takayuki Yoshino.

4. Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021–22

• Japanese Journal of Clinical Oncology., 2024 Oct;54(10)1071–1077.
• Hiroshi Imaoka, Keita Sasaki , Ryunosuke Machida, Hiroaki Nagano , Sohei Satoi, Masafumi Ikeda, Satoshi Kobayashi , Taro Yamashita , Takuji Okusaka, Akio Ido, Etsuro Hatano , Haruo Miwa , Masaki Ueno, Kazuhiko Nakao, Satoshi Shimizu, Hidekazu Kuramochi , Ryotaro Sakamori, Hidetaka Tsumura, Naohiro Okano, Kazuhiko Shioji, Hirofumi Shirakawa, Noriyuki Akutsu , Kunihiro Tsuji , Hiroshi Ishii , Kumiko Umemoto , Akinori Asagi, Makoto Ueno and on behalf of the JCOG Hepatobiliary and Pancreatic Oncology Group.

5. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.

• Targeted Oncology. 2024 Jul;19(4):575-585.
• Yoshinori Kagawa, Chaochen Wang, Yongzhe Piao, Long Jin, Yoshinori Tanizawa, Zhihong Cai, Yu Sunakawa.

6. Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan.


• Cancers (Basel).2024 Apr 15;16(8):1504.
• Marin Ishikawa, Kohei Nakamura, Ryutaro Kawano, Hideyuki Hayashi, Tatsuru Ikeda, Makoto Saito, Yo Niida, Jiichiro Sasaki, Hiroyuki Okuda, Satoshi Ishihara, Masatoshi Yamaguchi, Hideaki Shimada, Takeshi Isobe, Yuki Yuza, Akinobu Yoshimura, Hajime Kuroda, Seigo Yukisawa, Takuya Aoki, Kei Takeshita, Shinichi Ueno, Junichi Nakazawa, Yu Sunakawa, Sachio Nohara, Chihiro Okada, Ko Nishimiya, Shigeki Tanishima, Hiroshi Nishihara.

7. The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling.

• Target Oncol. 2024 May;19(3):459-471.
• Hiroyuki Yamamoto, Hiroyuki Arai, Ritsuko Oikawa, Kumiko Umemoto, Hiroyuki Takeda, Takuro Mizukami, Yohei Kubota, Ayako Doi, Yoshiki Horie, Takashi Ogura, Naoki Izawa, Jay A Moore, Ethan S Sokol, Yu Sunakawa.

8. A phase II study of long-course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE-2.

• Annals of Gastroenterological Surgery. 2024 August.
• Yoshinori Kagawa, Koji Ando, Mamoru Uemura, Jun Watanabe, Koji Oba, Yasunori Emi, Nobuhisa Matsuhashi, Naoki Izawa, Osamu Muto, Tatsuya Kinjo, Ichiro Takemasa, Eiji Oki.

9. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians.

• Frontiers in Health Services. 2024 Jul 12:4:1275496.
• Yuriko Sasahara, Yuki Takumoto, Kaname Watanabe, Hiroyuki Takeda, Kumiko Umemoto, Yu Sunakawa,Naoki Suzuki, Takashi Yoshioka, Satoshi Kobayashi, Makoto Ueno, Sho Nakamura, Manabu Akazawa andHiroto Narimatsu.

10. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.

• nature medicine. 16 September 2024.
• Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T.

11. Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.

• Clinical Cancer Research. 2024 Sep 13;30(18):4167-4178.
• Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y.

12. Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations.

• JCO Precision Oncology. 2024 Aug:8:e2300425.
• Takeda H, Yamamoto H, Oikawa R, Umemoto K, Arai H, Mizukami T, Ogawa K, Uchida Y, Nagata Y, Kubota Y, Doi A, Horie Y, Ogura T, Izawa N, Moore JA, Sokol ES, Sunakawa Y.

13. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

• Journal of Clinical Oncology. 2024 Aug 1:JCO2302626.
• Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, Komatsu Y, Esaki T, Sakai D, Doi A, Kajiwara T, Ono H, Asano M, Hirano N, Odegaard J, Fujii S, Nomura S, Bando H, Sato A, Yoshino T, Nakamura Y.

14. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.

• nature communications. 2024 Jul 13;15(1):5885.
• Osumi H, Shinozaki E, Nakamura Y, Esaki T, Yasui H, Taniguchi H, Satake H, Sunakawa Y, Komatsu Y, Kagawa Y, Denda T, Shiozawa M, Satoh T, Nishina T, Goto M, Takahashi N, Kato T, Bando H, Yamaguchi K, Yoshino T.

15. Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).

• Oncologist. 2024 Aug 5;29(8):e997-e1002.
• Sunakawa Y, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Takahashi M, Matsuyama J, Yabusaki H, Makiyama A, Suzuki T, Tsuda M, Yasui H, Hihara J, Takeno A, Inoue E, Ichikawa W, Fujii M.

16. 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1).

• J Hepatobiliary Pancreat Sci. 2024 Dec;31(12):886-896.
• Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, Kamata K, Yanagibashi H, Mizuno N, Kawamoto Y, Gotoh K, Shirakawa H, Okano N, Nomura T, Tanaka K, Takahashi A, Yagi S, Ohta K, Takayama Y, Miwa H, Nagano H, Kojima Y, Hisano T, Tahara M, Sakuma Y, Arai H, Nakamura I, Katayama H, Konishi M, Ueno M.

17. Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.

• J Journal of Hepato-Biliary-Pancreatic Sciences. 2024 Sep 30;8(1):214.
• Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astaturov I, Liu T, Lockhart AC, Korn WM, Shen L, Lenz HJ.

18. Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study.

• J NPJ Precision Oncology. 2024 Nov 5;12(11):e010326.
• Arai H, Gandhi N, Battaglin F, Wang J, Algaze S, Jayachandran P, Soni S, Zhang W, Yang Y, Millstein J, Lo JH, Sohal D, Goldberg R, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Korn WM, Lenz HJ.

19. An approach for improvement of the accuracy of cancer gene panel testing.

• J Int J Clin Oncol. 2024 May;29(5):571-581.
• Kiyomi Imoto, Hiroyuki Yamamoto, Chie Ohkawa, Naoki Shimada, Ryo Ikuzawa, Hiroyuki Takeda, Tatsuru Ohhara, Yasuyuki Kojima, Naoki Furuya, Ai Motoyoshi, Ohsuke Migita, Asami Kuga, Takayuki Keira, Hirotake Wakamatsu, Tomoo Sato, Nobuyuki Oike, Junki Koike, Yoshihisa Yamano, Yu Sunakawa.

20. Reply to L. Celio et al.

• British Journal of Cancer. 2024 Jun;130(12):1887-1888.
• Hiroko Minatogawa, Naoki Izawa, Takako Eguchi Nakajima.

21. A Case of Recurrent Gastric Cancer in Which Patient Education by a Pharmacist Helped Recover from Myasthenia Gravis Induced by Nivolumab.

• 日本臨床腫瘍薬学会雑誌. 130(38):7-13.
• Toshihiro Kobayashi, Ayako Tsuboya, Takashi Ogura, Kensuke Shinohara, Yuka Ito.

22. Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.

• Nature Communications. 2024 Nov 25;15(1):10217.
• Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, Tei M, Kochi M, Manaka D, Ohori H, Yamaguchi T, Sagawa T, Kotaka M, Kubota Y, Sekikawa T, Nakamura M, Takeuchi M, Ichikawa W, Fujii M, Tsuji A.

23. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.

• New England Journal of Medicine. 2025 Feb 6;392(6):566-576.
• Alison M Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V Liu, Benjamin A Weinberg, James M Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii-Saab, Grainne M O’Kane , Frans Opdam, Kim A Reiss, Andrew K Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon.

24. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.

• Journal of Gstroenterology. 2025 Feb.
• Hiroshi Imaoka, Masafumi Ikeda, Satoshi Kobayashi, Akihiro Ohba, Masayuki Ueno , Yuko Suzuki, Hidetaka Tsumura, Nana Kimura, Shinya Kawaguchi, Yasuyuki Kawamoto, Kohei Nakachi, Kunihiro Tsuji, Noritoshi Kobayashi, Reiko Ashida, Naohiro Okano , Kumiko Umemoto, Gou Murohisa, Ayumu Hosokawa, Akinori Asagi, Hiroko Nebiki, Rei Suzuki, Takeshi Terashima, Ryusuke Shibata, Kazuhito Kawata, Toshifumi Doi, Hiroshi Ohyama, Yohei Kitano, Kazuhiko Shioji, Hiroyuki Okuyama, Atsushi Naganuma, Yuji Negoro, Yasunari Sakamoto, Satoshi Shimizu, Chigusa Morizane, Makoto Ueno, Junji Furuse, Hiroaki Nagano.

25. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.

• British Journal of Cancer. 2024 Oct;131(7):1237-1245.
• Kentaro Sudo 1, Yoshiaki Nakamura 2 3, Makoto Ueno 4, Masayuki Furukawa 5, Nobumasa Mizuno 6, Yasuyuki Kawamoto 7, Naohiro Okano 8, Kumiko Umemoto 9, Akinori Asagi 10, Masato Ozaka 11, Koushiro Ohtsubo 12, Satoshi Shimizu 13, Nobuhisa Matsuhashi 14 15, Shinji Itoh 16, Toshihiko Matsumoto 17, Taroh Satoh 18, Hiroyuki Okuyama 19, Masahiro Goto 20, Hiroko Hasegawa 21, Yoshiyuki Yamamoto 22, Justin I Odegaard 23, Hideaki Bando 24 25, Takayuki Yoshino 24, Masafumi Ikeda 26, Chigusa Morizane 27.

26. Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.

• European Journal of Cancer. 2024 Oct;131(7):1237-1245.
• Hiroo Ishida, Yu Sunakawa, Yasuhiro Kodera, Kazuhiro Yoshida, Mitsugu Kochi, Yoshihiro Kakeji, Takeshi Sano, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.

27. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

• Nature Medicine. 2025 31(3):909-916.
• Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O’Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR.

28. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.

• J Gastroenterol. 2025 Mar;60(3):356-367.
• Hiroshi Imaoka , Masafumi Ikeda, Satoshi Kobayashi, Akihiro Ohba, Masayuki Ueno, Yuko Suzuki, Hidetaka Tsumura, Nana Kimura, Shinya Kawaguchi, Yasuyuki Kawamoto, Kohei Nakachi, Kunihiro Tsuji, Noritoshi Kobayashi, Reiko Ashida, Naohiro Okano, Kumiko Umemoto, Gou Murohisa, Ayumu Hosokawa, Akinori Asagi, Hiroko Nebiki, Rei Suzuki, Takeshi Terashima, Ryusuke Shibata, Kazuhito Kawata, Toshifumi Doi, Hiroshi Ohyama, Yohei Kitano, Kazuhiko Shioji, Hiroyuki Okuyama, Atsushi Naganuma, Yuji Negoro, Yasunari Sakamoto, Satoshi Shimizu, Chigusa Morizane, Makoto Ueno, Junji Furuse, Hiroaki Nagano.

29. Optimizing Organ Preservation Strategies through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results from the CROC Multi-Institutional Phase II Clinical Trial.

• International Journal of Radiation Oncology • Biology • Physics, 2024 Dec 1;120(5):1353-1362.
• Chikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, Hiroki Hara, Takako Yoshii, Hirofumi Fujii, Hironori Yamaguchi, Takako Eguchi Nakajima, Naoki Izawa, Takayuki Ando, Motoo Nomura, Takashi Kojima, Keishi Yamashita, Shogo Kawakami, Hiromichi Ishiyama, Yusuke Inoue, Yasutoshi Sakamoto, Hiroki Sasaki, Hideki Ishikawa, Ayumu Hosokawa, Yasuo Hamamoto,　Manabu Muto, Makoto Tahara, Wasaburo Koizumi.

30. Naldemedine for opioid-induced constipation in patients with cancer: A multicenter, double-blind, randomized, placebo-controlled trial.

• Journal of Clinical Oncology, 2024 Dec 10;42(35):4206-4217.
• Jun Hamano, Takahiro Higashibata, Takaomi Kessoku, Shinya Kajiura, Mami Hirakawa, Shunsuke Oyamada, Keisuke Ariyoshi, Takeshi Yamada, Yoshiyuki Yamamoto, Yasuyuki Takashima, Kosuke Doki, Masato Homma, Bryan J Mathis, Tsumugi Jono, Tomoki Ogata, Kosuke Tanaka, Yuki Kasai, Michihiro Iwaki, Akiko Fuyuki, Atsushi Nakajima, Ryuji Hayashi, Takayuki Ando, Naoki Izawa, Yuko Kobayashi, Yoshiki Horie, Tatsuya Morita.



《症例報告》

1. A case of multiple bone metastases during the course of non-invasive bladder and prostate cancer.

• IJU Case Reports. 02 February 2025, 8, 158–161.
• Keisuke Matsubara, Nozomi Hayakawa, Yohei Kubota, Nobuyuki Ohike, Yu Sunakawa, Junki Koike, Eiji Kikuchi.

過去の業績

• 2023年度（PDF）
• 2022年度（PDF）
• 2021年度（PDF）
• 2020年度（PDF）
• 2019年度（PDF）
• 2018年度（PDF）
• 2017年度（PDF）
• 2016年度（PDF）
• 2015年度（PDF）
• 2014年度（PDF）

書籍のご紹介

チャートでわかる！
がん外来化学療法のリアル

チームで解決する18の副作用

（編集）聖マリアンナ医科大学病院腫瘍センター

ご購入はこちら